• Lunai Bioworks entered an exclusive worldwide license and collaboration with Tanaist to expand its Parkinson’s disease discovery and validation platform.
• Deal adds human cellular phenotyping to test whether AI-identified patient subtypes reproduce across cohorts and map to measurable cellular mechanisms.
• Lunai secured exclusive rights to Tanaist’s cellular phenotyping technology in Parkinson’s for programs based on Lunai patient phenoclusters.
• Work builds on Augusta AI analysis of 650 PPMI participants with 4,500 proteomic probes that identified three Parkinson’s subtypes.
• Lunai will own collaboration-generated analyses, biomarker findings, and related results; Tanaist retains ownership of its underlying platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220920PR_NEWS_USPR_____LA53825) on September 22, 2026, and is solely responsible for the information contained therein.